UPDATE: Goldman Sachs Initiates Coverage on ViroPharma at Neutral

According to Goldman Sachs, ViroPharma VPHM coverage is initiated with a Neutral rating. Goldman Sachs said that it initiates on ViroPharma (VPHM) with a Neutral rating and a 12-month price target of $26. VPHM is a profitable, mid-cap biotechnology company with three marketed drugs. “We view VPHM as an attractive growth story in mid-cap biotech but outstanding questions on expansion of manufacturing capacity and limited pipeline catalysts over the next several quarters keep us at Neutral.” ViroPharma closed yesterday at $27.02.